FSHR and cancer: A novel variant of the lytic peptide phor, composed of 18 amino acids (Phor18) conjugated to FSHβ has been shown to inhibit the growth of PC-3 xenografts by targeting FSHR-expressing cancer or endothelial cells of tumor vessels (Aggarwal et al. 2015).